AKT1 and endometrial cancer: In particular, PTEN loss and mutations are observed in >50% of endometrial cancers (ECs) and can be an early oncogenic event that drives endometrial tumorigenesis through hyperactivation of the PI3K–AKT signaling pathway (5).